Fulgent Genetics (MEX:FLGT) Total Current Assets : MXN7,312 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Fulgent Genetics's total current assets for the quarter that ended in Jun. 2024 was MXN7,312 Mil.

Fulgent Genetics Total Current Assets Historical Data

The historical data trend for Fulgent Genetics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Total Current Assets Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

699.31

10,415.77

12,553.75

12,241.01

8,620.29

Fulgent Genetics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Total Current Assets	Get a 7-Day Free Trial															9,056.93	9,577.87	8,620.29	6,414.60	7,311.63

Fulgent Genetics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Fulgent Genetics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	7199.695	+	975.086	+	98.909	+	346.597
	=	8,620

Fulgent Genetics's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	5710.486	+	1167.265	+	128.717	+	305.158
	=	7,312

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Fulgent Genetics (MEX:FLGT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Fulgent Genetics's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	5710.486	-	1894.134	+	0.75 * 1036.423	+	0.5 * 128.717
=	4,658

Fulgent Genetics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.